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Background: Persons with diabetes and depression have increased risk of complications and increased mortality.
We aimed to investigate the prevalence, clinical characteristics and impact with regard to glycosylated haemoglobin
(HbA1c) of depressive disorders in persons with type 1 diabetes at an outpatient specialist diabetes clinic.
Findings: A total of 51 persons with type 1 diabetes were diagnosed according to Mini International Neuropsychiatric
Interview (M.I.N.I) with regard to dysthymia and previous or ongoing depressive episodes during spring 2005. HbA1c
was measured at the day of the interview, and self-reported information on family history of depressive disorders was
obtained. Eight persons (16%; 95% CI: 7%, 29%) were in the midst of a major depressive episode, 4 of these also
reported a previous episode of depression. Seven of the 8 persons with an ongoing major depressive episode met the
criteria for melancholia. Three persons (6%) met the criteria for dysthymia, and 6 persons (12%) had previous episode(s)
of depression, without being currently depressed. The 17 (33%; 95% CI: 21%, 48%) persons with ongoing and/or
previous depressive disorder had increased HbA1c (8.5%; 95% CI: 7.6%, 9.4%) compared to those without depressive
disorders (7.9%; 95% CI: 7.5%, 8.3%), although the difference did not reach statistical significance.
Conclusions: Persons with type 1 diabetes had a high prevalence of depressive disorders, mainly depressive episodes
that also met the criteria for melancholia, a subtype often considered a more serious and “biologic” form of depression.
We were not able to demonstrate that persons with depressive disorders had poorer regulated diabetes compared to
those without depressive disorders.
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Introduction
Diabetes and depression are prevalent diseases in the gen-
eral population, and often present as co-morbid conditions
[1]. Depression in persons with diabetes is associated with
worsening of diabetes related outcomes [2-7], which has
led the American Diabetes Association to recommend
screening for depression, anxiety and psychosocial prob-
lems as a part of the medical management of diabetes [8].
There are a few studies on the prevalence of depressive
symptoms among persons with type 1 diabetes [9-11],* Correspondence: line.iden.berge@gmail.com
1Haukeland University Hospital, Division of Psychiatry/Institute of Clinical
Medicine, Section of Psychiatry, University of Bergen, Bergen, Norway
2Research group for lifestyle epidemiology, Department of Global Public
Health and Primary Health Care, University of Bergen, Kalfarveien 31, 5018
Bergen, Norway
Full list of author information is available at the end of the article
© 2013 Berge et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orbut the majority of these studies have assessed depres-
sion using self-reported questionnaires rather than a val-
idated diagnostic interview. A meta-analysis including
511 persons from controlled studies using diagnostic
interview found a non-significant OR of 2.4 (95% CI: -0.7,
5.4) for depression in type 1 diabetes [12]. The authors of
a recently published review on the epidemiology of de-
pression and diabetes suggest that there is a shortage of
data on the prevalence and characteristics of depression in
persons with type 1 diabetes [13].
This study was designed to ascertain the frequency
and clinical characteristics of depressive disorders in a
group of persons with type 1 diabetes. To further inves-
tigate the impact of depressive disorders in diabetes, we
compared the HbA1c levels between the groups of per-
sons with ongoing and/or previous depressive disorders
to those without depressive disorders.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Persons were recruited consecutively when attending a
routine control at a specialist outpatient unit for persons
with diabetes at the Department of Endocrinology at
Haukeland University Hospital, Bergen, Norway, during
spring 2005. The persons were in need of regular visits
at a specialised diabetic outpatient clinic in order to
maintain an acceptable HbA1c level. Persons were eli-
gible for inclusion if they had type 1 diabetes diagnosed
by a physician, were between the age of 18 and 70 years,
and did not suffer from organic brain syndrome (defined
as decreased mental function due to medical diseases other
than psychiatric illnesses) [14]. Fifty-eight consecutive per-
sons were invited to participate over a 5 week period, and
54 agreed. Three persons were diagnosed with type 2 dia-
betes and were excluded from the study. No persons were
excluded due to the age-criteria or possible organic brain
syndrome, giving a final sample of 51 persons.
Psychiatric diagnoses were assessed using five modules
included in the Mini International Neuropsychiatric
Interview (M.I.N.I) [15], Norwegian Version 5.0.0, part A
(ongoing or previous major depressive episode, major de-
pressive episode with melancholia), part B (dysthymia),
part D (mania/hypomania) and part E (panic attacks). The
same physician, who has training in the use of M.I.N.I.,
conducted all the interviews (L.I.B). During these inter-
views, we also obtained self-reported information about
current medication, whether there were first degree rela-
tives with depressive disorders, and the year of onset of
diabetes. HbA1c (% and mmol/mol units) was measured at
the day of the psychiatric interview by the laboratory of
Biochemistry at the University Hospital of Bergen.
Confidence intervals for prevalence estimates were cal-
culated based on a binominal distribution. We estimated
the differences in HbA1c between groups of persons
with and without ongoing and/or previous depressive
disorders using a linear regression model adjusting for
sex, age and duration of diabetes. Age and duration of
disease was used as continuous variables. The study was
approved by the Regional Ethical Committee, and all
participants provided a written informed consent. The
statistical software used was the SPSS version 20.
Results
Twenty-five (47%) of the persons were men. Age ranged
from 18 to 68 years with a mean age of 39 years. Mean
age at the time of onset of diabetes was 24 years, and
mean duration of the disease was 15 years. According to
M.I.N.I., 17 persons (33%; 95% CI: 23%, 48%) met the
criteria for either an ongoing major depressive episode,
ongoing dysthymia or (a) previous depressive episode(s)
(i.e.: ongoing and/or previous depressive disorders). Of
these, 8 persons (16%; 95% CI: 7%, 29%) had an ongoing
major depressive episode, 3 persons (6%) met the criteriafor ongoing dysthymia and 6 persons (12%) had previous
episodes of depression without currently meeting the cri-
teria for major a depressive episode or dysthymia. Seven of
the 8 persons who met the criteria for an ongoing major
depressive episode also met the criteria for depression
with melancholia, while 4 of them reported a previous epi-
sode of depression. Five persons (10%) met the criteria for
panic disorders, of these, 3 were also diagnosed with an
ongoing major depressive episode, while 2 had a previous
history of depression. One person (2%) met the criteria for
a previous episode with hypomania; this person also
reported previous episodes of depression. None met the
criteria for previous episodes with mania.
In total, 39% of the persons reported a first degree
relative with a history of depression (Table 1). Sixty-four
percent of the persons with an ongoing major depressive
episode or dysthymia had a first degree relative with a
history of depression, whereas the percentages among
those who had previously been depressed or never had
been depressed were 33% and 32%, respectively. Among
the 17 persons with either ongoing and/or previous de-
pressive disorder, 53% reported a first degree relative
with a history of depression.
The 11 persons with a major depressive disorder or
dysthymia had a mean HbA1c of 8.5% (Table 1). The
HbA1c value of one person in this group was missing.
The 6 persons with(a) previous episode(s) of depression
had mean HbA1c of 8.6%, while persons with depressive
disorders had a mean HbA1c of 7.9%. The 17 persons
with ongoing and/or previous depressive disorders had a
mean HbA1c of 8.5%. Persons with panic disorders had
a mean HbA1c of 9.1% (95% CI: 5.9%, 12.3%) (equal to
76.2 (95% CI: 41.4, 111.0) in mmol/mol). Using a linear
regression analysis adjusting for sex, age and duration of
diabetes the difference in HbA1c between those with on-
going and/or previous depressive disorders and those
without was 0.79 (95% CI: -0.09, 1.67) (Table 2).
Seven of the 8 persons who met the criteria for an on-
going major depressive episode also met the criteria for
melancholia. Fifthy-seven percent of these were women,
and 57% (95% CI: 18%, 90%) reported a first degree rela-
tive with a history of depression. Mean HbA1c was 8.9%
(95% CI: 6.4%, 11.4%) (equal to 71.6 (95% CI: 49.1, 94.1)
in mmol/mol).
One person with an ongoing major depressive episode
and one with ongoing dysthymia were on treatment with
a selective serotonin reuptake inhibitor (SSRI), while an-
other person with an ongoing major depressive episode
used a selective beta 1-antagonist, which has depression
as a known side-effect.
Discussion
Using a validated clinical diagnostic interview for psychi-
atric disorders on persons with type 1 diabetes assessed
Table 1 Characteristics of persons with type 1 diabetes according to depressive disorder
% female Percentage of first degree relative
with depression (95% CI)
Mean HbA1c (%)
(95% CI)
Mean HbA1c (mmol/mol)
(95% CI)
Previous and/ or ongoing depressive disorders (n = 17) 76 53 (28, 77) 8.5 (7.6, 9.4) 66.8 (59.5, 78.1)
Ongoing major depression or dysthymia (n = 11) 64 64 (31, 89) 8.5 (7.0, 10.0)* 68.1 (53.5, 82.7)*
Previous episode(s) of depression (n = 6) 100 33 (4, 78) 8.6 (7.6, 9.5) 70.1 (59.7, 80.6)
No depressive disorder (n = 34) 41 32 (20, 54) 7.9 (7.5, 8.3)* 62.9 (58.7, 67.2)*
All persons with type 1 diabetes (n = 51) 53 39 (26, 54) 8.1 (7.7, 8.5) 64.9 (60.8, 69.1)
*one value of HbA1c missing.
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with an ongoing major depressive episode, while 33%
met the criteria for either ongoing and/or previous de-
pressive disorders. Interestingly, 7 of 8 persons with a
major depressive episode met the criteria for melancho-
lia. Further, we found a high prevalence of family history
of depression among persons with type 1 diabetes, even
among those who did not have a history of depression
themselves.
A German study of 313 persons with newly diagnosed
type 1 diabetes found that 5.8% met the criteria for a
major depressive episode using Diagnostic Interview for
Mental Disorders (DIMD-short version), a significant
higher prevalence than that of the reference group of
2.7% [16]. In spite of the rather marked difference from
the estimate in our study, the estimate with confidence
intervals for major depressive episode in persons with
type 1 diabetes from the German study overlaps with
the confidence interval found in the present study. Still,
a possible difference in the two prevalence estimates
could be attributed to differences in the duration of the
disease; the persons in the German study had had dia-
betes for an average of 4 weeks, while average duration
of diabetes in our population reached 15 years.
Other investigators have used self-reported outcomes
to estimate the prevalence of depressive symptomatology
in persons with diabetes. A study of 273 persons with
type 1 diabetes in an outpatient clinic in the UK found
that 6% reported moderate to severe depression on the
Hospital anxiety and depression scale (HADS) [9]. ClinicalTable 2 Linear regression analysis with HbA1c as dependent
variable and ongoing and/or previous depressive disorders,
sex, age and duration of disease as independent variables
Unstandardized β
coefficients (95% CI)
p-value
Ongoing and/or previous depressive
disorders
0.79 (-0.09, 1.67) 0.08
Sex (ref male) −0.63 (-1.45, 0.18) 0.13
Age (continuous) −0.01 (-0.04, 0.02) 0.48
Duration of disease (continuous) −0.02 (-0.06, 0.02) 0.28
Constant 9.55 (7.80, 11.3) <0.001significant levels of depressive symptoms (scores ≥16) were
reported by 14% of the 264 persons with type 1 diabetes on
the Beck Depression Inventory (BDI) and by 18% on
Center for Epidemiological Studies of Depressions Scale
(CES-D) in the Pittsburg Epidemiology of Diabetes Com-
plications study [11]. Further, the Coronary Artery Calci-
fication in Type 1 Diabetes Study found as many as 32%
of 458 persons with type 1 diabetes either reported using
antidepressant agents or scored above 14 on self-
reported symptoms of depression on the Beck Depres-
sion Inventory-2, compared to 16% in the control group
of 546 persons without diabetes [10]. A possible limita-
tion when using antidepressant agents as a measure of
depression among persons with diabetes might be that
antidepressant agents are indicated in treatment of
neuropathic pain, a common complication in diabetes.
Still, one argues it can be regarded as a valid measure of
depression in populations with diabetes as a substantial
comorbidity between neuropathic pain and depression
has been shown [17].
Overall, these estimates are in line with our findings
using a diagnostic tool, suggesting that as many as one
sixth of persons with type 1 diabetes may suffer from a
current major depressive episode. Interestingly, we also
found a high prevalence of melancholic depression among
the persons with an ongoing major depressive episode, a
subtype often considered the classic form of “biological”
depression, with anhedonia and psychomotor retardation
as core features [18,19].
First degree relatives of persons with depression have
an increased risk of developing depression (OR of 2-3)
[20]. This is compatible with our finding that 53% of per-
sons with type 1 diabetes and previous and/or ongoing
depressive disorders reported a fist degree relative with
a history of depression. However, we similarly found
that as many as 32% of the persons with diabetes with-
out any depressive disorder reported a first degree rela-
tive with depression. A study from 1980 investigating
first degree relatives of persons with psychiatric disor-
ders found that persons in the control group consisting
of surgical patients had an approximate risk of 7% of
unipolar depression [21]. This control group, however,
included persons with psychiatric disorders. Our finding
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among persons with diabetes without any personal his-
tory of depression could indicate a possible genetic
component of depression in persons with diabetes.
We found in that persons with previous and/or on-
going depression had higher HbA1c levels than those
without depression, although the difference was not sig-
nificant possibly due to the rather small sample size.
Several previous studies have assessed this association. A
meta-analysis from 2000 concluded that depression was
significantly associated with hyperglycaemia and that
type 1 diabetes and criteria-based diagnosis (in contrast
to self-report measures) gave the highest effect sizes of
0.19 and 0.28, respectively [22]. No recent studies have
investigated the association between HbA1c and a diag-
nosis of depression using a diagnostic tool such as the
M.I.N.I. among persons with type 1 diabetes; however,
some studies have examined the association using self-
reported measures of depression among persons with
type 1 diabetes. In the previously mentioned Coronary
Artery Calcification in Type 1 Diabetes Study, current
HbA1c was not correlated with self-reported measures
of depression, but persons with type 1 diabetes with a
history of depression reported a slightly higher HbA1c
than those without a history of depression [10]. A study
of persons with type 1 diabetes at diabetic clinics in the
Netherlands found that HbA1c ≥ 8.5% more than dou-
bled the odds of depressive affect defined as a CES-d
score ≥16, after adjusting for demographic factors [23].
Further, another study from the same group in the
Netherlands found that self-reported measures of de-
pressed mood, sleeping difficulties, appetite problems
and psychomotor disturbances were related to higher
HbA1c values at one year follow up and that the associa-
tions were more pronounced among persons with type 1
than type 2 diabetes [24]. Interestingly, self-reported
symptoms of anhedonia, a core feature of melancholic
depression, was associated with suboptimal glycemic con-
trol (defined as HbA1c ≥7%), while no such association
was found with symptoms of depression in a recent study
of about 5700 persons with type 2 diabetes, indicating that
distinct characteristics of depression rather than depres-
sion pr se might explain the association between depres-
sion and glycemic control [25].
Medication might influence a persons’ mood and
HbA1c-value. Some serotonergic antidepressants reduce
hyperglycaemia and increase the insulin sensitivity whereas
some noradrenergic antidepressants have opposite effects
[26]. However, of the 11 persons with ongoing depressive
episode or dysthymia, only one person with a major de-
pressive episode and one with dysthymia used SSRI, and
none used noradrenergic antidepressants. One person in
the midst of a major depressive episode used a selective
beta1-antagonist, with a known side-effect of depression.We find it unlikely that our results were meaningfully in-
fluenced by currently used medication.
The main limitation of the study is the representativity
of our sample, the lack of control group and that the
prevalence of depressive disorders among family mem-
bers was assessed by self-report. One should generalize
the results with caution, as the persons included were in
need of treatment at a specialist unit at a university hos-
pital and it is likely that these persons have a condition
that is more difficult to treat than the rest of the popula-
tion with type 1 diabetes. Still, persons were included
consecutively making the study population representa-
tive at least for those entering this type of specialist unit.
In addition, we did not have information on previous
and current psychotherapeutic treatments or knowledge
about life-events that could have been relevant with re-
gard to depressive disorders. Finally, the small sample
size is reflected in the wide confidence intervals.
In conclusion, persons with type 1 diabetes attending a
specialist outpatient unit had a high prevalence of de-
pressive disorders, mainly depressive episodes that also
met the criteria for melancholia. As depression in per-
sons with diabetes is associated with increased risk of
complications and increased mortality, and melancholic
depression is considered a more severe subtype with low
spontaneous remission rate, the clinicians should pay
special attention to this group. Future studies should
examine prevalence and clinical characteristics of de-
pressive disorders using validated diagnostic interviews
in a larger sample of persons with type 1 diabetes as well
as in a control group recruited from the general popula-
tion. Of special importance would be to reproduce the
finding of a high prevalence of melancholic depression
among persons with type 1 diabetes.Abbreviations
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